Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 0.43 |
| ▸ | HTR5A | P47898 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047129 | 0.83 | TRPA1 (0.39) | TRPA1HTR5A | |
| SCHEMBL14817734 | 0.77 | TRPA1 (0.46) | TRPA1HTR5ATSHR | |
| SCHEMBL14531930 | 0.73 | TRPA1 (0.50) | TRPA1HTR5ATSHR | |
| SCHEMBL12188780 | 0.73 | TRPA1 (0.42) | TRPA1HTR5ATSHR | |
| SCHEMBL12558442 | 0.68 | TRPA1 (0.49) | TRPA1 | |
| SCHEMBL242542 | 0.66 | — | — | |
| SCHEMBL29517242 | 0.66 | — | — | |
| SCHEMBL7572467 | 0.65 | TRPA1 (0.55) | TRPA1 | |
| Hydrochloric Acid SCHEMBL31416539 | 0.65 | TRPA1 (0.43) | TRPA1TSHR | |
| SCHEMBL27462406 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190144426-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180030034-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030034-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| US-9822096-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160362396-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-15 | — | — | US | disclosed |
| US-9458164-B2 | Pyrrolopyridazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458114-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20070203157-A1 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-30 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885HTR5A 3901/4885TSHR 2250/4885 |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885HTR5A 3901/4885TSHR 2250/4885 |
| US-20160362396-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | TRPA1 3080/4885HTR5A 3901/4885TSHR 2250/4885 |
| US-20180030034-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | TRPA1 86/4885HTR5A 2396/4885TSHR 566/4885 |
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | TRPA1 3026/4885HTR5A 2584/4885TSHR 169/4885 |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | TRPA1 2791/4885HTR5A 1432/4885TSHR 121/4885 |
| US-20070203157-A1 | Heterocyclic dihydropyrimidine compounds | KCNQ5, KCNH2, KCNQ2 | TRPA1 81/4885HTR5A 821/4885TSHR 1138/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNQ5, KCNQ2 | TRPA1 110/4885HTR5A 999/4885TSHR 3471/4885 |
| US-20190144426-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | TRPA1 131/4885HTR5A 1865/4885TSHR 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.